Why amivantamab stops working in certain lung cancers
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how and why lung cancers with a specific EGFR mutation (exon 20 insertion) become resistant to the drug amivantamab. It collects blood and tumor samples from patients whose cancer has progressed on amivantamab to better understand resistance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) that has an EGFR exon 20 insertion mutation.
- You are receiving amivantamab as your only treatment (not with other drugs).
- Your cancer has gotten worse (progressed) while on amivantamab.
- You are willing to give blood samples and, if possible, a tumor biopsy when your cancer progresses.
- You are 18 years or older and are covered by French National Health Insurance or a third-party payer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
This trial tests a combination of two targeted therapies (amivantamab and lazertinib) or amivantamab with chemotherapy for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if these treatments work better together than current options.
This study looks at how well a treatment called amivantamab works in people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). It aims to track real-world outcomes in patients who are starting amivantamab for the first time.
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
This trial tests a new drug, amivantamab, given before surgery for people with a specific EGFR-mutated lung cancer. It aims to shrink tumors and improve surgical outcomes, and may be combined with standard chemotherapy in some patients.
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.